Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Misses Revenue Estimates

Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of$ 0.18. This compares to loss of $0.22 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 5.56%. A quarter ago, it was expected that this drugmaker would post a loss of$ 0.18 per share when it actually produced a loss of $0.20, delivering a surprise of -11.11%. Over the last four quarters, the company ...